Skip to content
Research Article Open access CC BY 4.0

Commentary on Article: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents (NEJM, Nov 21 2019)

A. M. Meer Ahmad

Asian Journal of Research in Infectious Diseases · pp. 21–28 · Published 18 Feb 2020

10.9734/ajrid/2020/v3i230123

Abstract

In this Letter to the Editor, this author comments on the article in the NEJM (Nov 21 2019) in the above title on the TAK-003 Dengue vaccine Phase III trial from a point of comparing with the predecessor, the CYD-TDV, beside comparing the TAK-003 and Severe dengue, and the TAK-003 and hospitalizations. The author also queries why the vaccine must be a chimeric-vaccine, questions the sample-size in the Phase III trial and questions the Serious Adverse Events reported observed in the trial. He write on Antibody Directed Enhancement in a relation to the TAK-003. The author make Additional Observation and seek certain Explanation.

Tetravalent dengue vaccine TAK-003 CYD-TDV Phase III trial efficacy safety severe dengue dengue hospitalization chimeric vaccine sample-size serious side effect antibody-directed enhancement.

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.